- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 2.90 Å
- Oligo State
- homo-trimer
- Ligands
- 19 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 3 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-FUC.6: 3 residues within 4Å:- Chain A: A.703, E.1069, N.1071
No protein-ligand interaction detected (PLIP)NAG-NAG-FUC.15: 3 residues within 4Å:- Chain B: A.703, E.1069, N.1071
No protein-ligand interaction detected (PLIP)NAG-NAG-FUC.26: 3 residues within 4Å:- Chain C: A.703, E.1069, N.1071
No protein-ligand interaction detected (PLIP)- 6 x NAG- NAG- MAN: alpha-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-MAN.7: 4 residues within 4Å:- Chain A: N.1095, T.1097, H.1098, F.1100
No protein-ligand interaction detected (PLIP)NAG-NAG-MAN.8: 1 residues within 4Å:- Chain A: N.1131
No protein-ligand interaction detected (PLIP)NAG-NAG-MAN.16: 4 residues within 4Å:- Chain B: N.1095, T.1097, H.1098, F.1100
No protein-ligand interaction detected (PLIP)NAG-NAG-MAN.17: 1 residues within 4Å:- Chain B: N.1131
No protein-ligand interaction detected (PLIP)NAG-NAG-MAN.27: 4 residues within 4Å:- Chain C: N.1095, T.1097, H.1098, F.1100
No protein-ligand interaction detected (PLIP)NAG-NAG-MAN.28: 1 residues within 4Å:- Chain C: N.1131
No protein-ligand interaction detected (PLIP)- 29 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
NAG.29: 2 residues within 4Å:- Chain A: Y.28, N.61
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain A: N.122, T.124, N.125
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain A: K.147, N.148, N.149, M.153
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain A: N.165
- Chain C: Y.348, I.465
Ligand excluded by PLIPNAG.33: 5 residues within 4Å:- Chain A: T.108, N.234, T.236
- Chain C: R.454, K.459
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain A: E.278, N.279
- Chain C: K.555
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain A: G.336, F.339, N.340
Ligand excluded by PLIPNAG.36: 1 residues within 4Å:- Chain A: N.600
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain A: N.654
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain A: N.706, G.1128
- Chain B: D.793
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain A: N.1155
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain B: C.15, V.16, N.17
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain B: Y.28, N.61
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain B: K.147, N.148, N.149
Ligand excluded by PLIPNAG.43: 1 residues within 4Å:- Chain B: N.234
Ligand excluded by PLIPNAG.44: 1 residues within 4Å:- Chain B: N.328
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain B: G.336, N.340
Ligand excluded by PLIPNAG.46: 1 residues within 4Å:- Chain B: N.600
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain B: H.652, N.654
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain B: N.706, G.1128
- Chain C: D.793
Ligand excluded by PLIPNAG.49: 1 residues within 4Å:- Chain B: N.1155
Ligand excluded by PLIPNAG.50: 2 residues within 4Å:- Chain C: Y.28, N.61
Ligand excluded by PLIPNAG.51: 3 residues within 4Å:- Chain C: K.147, N.148, N.149
Ligand excluded by PLIPNAG.52: 2 residues within 4Å:- Chain C: N.328, Q.577
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain C: F.339, N.340, L.365
Ligand excluded by PLIPNAG.54: 1 residues within 4Å:- Chain C: N.600
Ligand excluded by PLIPNAG.55: 2 residues within 4Å:- Chain C: H.652, N.654
Ligand excluded by PLIPNAG.56: 3 residues within 4Å:- Chain A: D.793
- Chain C: N.706, G.1128
Ligand excluded by PLIPNAG.57: 2 residues within 4Å:- Chain C: N.1155, H.1156
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cai, Y. et al., Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science (2021)
- Release Date
- 2021-07-07
- Peptides
- Spike glycoprotein: ABC
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
C
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 2.90 Å
- Oligo State
- homo-trimer
- Ligands
- 19 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 3 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 6 x NAG- NAG- MAN: alpha-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 29 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Cai, Y. et al., Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science (2021)
- Release Date
- 2021-07-07
- Peptides
- Spike glycoprotein: ABC
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
C